Skip to Content

Immediate Start of ART for HIV May Impact 10-Year Risk for Cancer

TUESDAY, March 16, 2021 -- For people with HIV, deferral of antiretroviral therapy (ART) has a small effect on increasing the 10-year risk for cancer, according to a study published online March 16 in the Annals of Internal Medicine.

Frédérique Chammartin, Ph.D., from the University of Basel in Switzerland, and colleagues estimated the long-term risk difference for cancer with an immediate ART strategy in the Data collection on Adverse events of anti-HIV Drugs study. Data were included for 8,318 HIV-positive persons. The 10-year risks for non-AIDS-defining and AIDS-defining cancer were compared for immediate versus deferred ART initiation strategies.

The researchers identified 231 cases of non-AIDS-defining cancer and 272 cases of AIDS-defining cancer during 64,021 person-years of follow-up among HIV-positive persons (median age, 36 years). With immediate ART, the 10-year risks for non-AIDS-defining and AIDS-defining cancer were 2.97 and 2.50 percent, respectively. When deferring ART to CD4 counts less than 500 x 109 cells/L and less than 350 x 109 cells/L, the 10-year absolute risk differences were 0.12 (95 percent confidence interval, −0.01 to 0.26) and 0.29 (95 percent confidence interval, −0.03 to 0.73) percentage points, respectively, for non-AIDS-defining cancer and 0.32 (95 percent confidence interval, 0.21 to 0.44) and 1.00 (95 percent confidence interval, 0.67 to 1.44) percentage points, respectively, for AIDS-defining cancer compared with immediate ART initiation.

"We observed that strategies promoting deferral of ART initiation in ART-naive, HIV-positive persons are associated with a small increase in risk for AIDS-defining cancer," the authors write.

Several pharmaceutical companies provided funding for the study.

Abstract/Full Text (subscription or payment may be required)

© 2021 HealthDay. All rights reserved.

Read this next

Cutaneous AEs Linked to Immune Checkpoint Inhibitor Therapy

TUESDAY, April 20, 2021 -- Cutaneous immune-related adverse events (irAEs) are associated with initiation of immune checkpoint inhibitor (ICI) treatment in cancer patients,...

42 Percent of Transgender Women With Valid HIV Test Are HIV+

MONDAY, April 19, 2021 -- Forty-two percent of transgender women with a valid HIV test result have a positive result, with considerable regional and ethnic/racial variation,...

One-Fourth of HIV Patients Report Experiencing Intimate Partner Violence

FRIDAY, April 16, 2021 -- One in four people with HIV experience intimate partner violence, according to a study published online March 31 in the American Journal of Preventive...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.